Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD
Tóm tắt
There is a disproportionate burden of human papillomavirus (HPV) –related genital tract disease in patients with CKD and kidney transplantation; therefore, the potential effect of the quadrivalent HPV vaccine (Gardasil; Merck GmbH, Darmstadt, Germany) is profound. Immune abnormalities associated with CKD and immunosuppression may prevent optimal vaccine response. Our objective was to determine antibody response to the HPV vaccine in adolescent girls with CKD.
This cohort study conducted from 2008 to 2012 included 57 girls aged 9–21 years old with CKD (
Antibody response to all four HPV genotypes was 100% in the CKD and dialysis groups with samples drawn at <12 and ≥12 months after dose 3 of the HPV vaccine. Among patients with transplants, the percentages of patients achieving seropositivity were significantly lower at blood draw 2 for HPV genotypes 6 (63.6%;
Antibody response to the quadrivalent recombinant HPV vaccine was robust and sustained in girls and young women with CKD and on dialysis. A less robust response to the vaccine was observed among those with a kidney transplant. Additional study is needed to determine if vaccination before kidney transplantation or an alternative vaccination regimen would benefit transplant recipients.
Từ khóa
Tài liệu tham khảo
Dias, 2005, Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18., Clin Diagn Lab Immunol, 12, 959
Brunner, 1995, Malignancies after renal transplantation: The EDTA-ERA registry experience., Nephrol Dial Transplant, 10, 74, 10.1093/ndt/10.supp1.74
Kessler, 2006, Excess risk of cancer in renal transplant patients., Transpl Int, 19, 908, 10.1111/j.1432-2277.2006.00383.x
Leigh, 1995, Skin cancer and warts in immunosuppressed renal transplant recipients., Recent Results Cancer Res, 139, 69, 10.1007/978-3-642-78771-3_6
Kasiske, 2004, Cancer after kidney transplantation in the United States., Am J Transplant, 4, 905, 10.1111/j.1600-6143.2004.00450.x
Marangi, 1994, Hepatitis B virus infection in chronic uremia: Long-term follow-up of a two-step integrated protocol of vaccination., Am J Kidney Dis, 23, 537, 10.1016/S0272-6386(12)80375-1
Sezer, 2000, Factors influencing response to hepatitis B virus vaccination in hemodialysis patients., Transplant Proc, 32, 607, 10.1016/S0041-1345(00)00914-3
Schulman, 1992, Response to measles-mumps-rubella vaccine in children on dialysis., Pediatr Nephrol, 6, 187, 10.1007/BF00866312
Cavdar, 2003, The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients., Scand J Urol Nephrol, 37, 71, 10.1080/00365590310008749
Suga, 1990, Influenza antibody titers after vaccination of chronic renal failure patients; before and during hemodialysis, or on continuous ambulatory peritoneal dialysis., Tokai J Exp Clin Med, 15, 245
Fuchshuber, 1996, Pneumococcal vaccine in children and young adults with chronic renal disease., Nephrol Dial Transplant, 11, 468, 10.1093/oxfordjournals.ndt.a027313
Krüger, 2001, A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients., Am J Kidney Dis, 38, 1264, 10.1053/ajkd.2001.29223
Fivush, 1998, Immunization guidelines for pediatric renal disease., Semin Nephrol, 18, 256
Schwartz, 2009, New equations to estimate GFR in children with CKD., J Am Soc Nephrol, 20, 629, 10.1681/ASN.2008030287
Levey, 2009, A new equation to estimate glomerular filtration rate., Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006
Muñoz, 2009, Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial., Lancet, 373, 1949, 10.1016/S0140-6736(09)60691-7
Block, 2006, Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women., Pediatrics, 118, 2135, 10.1542/peds.2006-0461
Smith, 2013, Pediatric kidney transplant practice patterns and outcome benchmarks, 1987-2010: A report of the North American Pediatric Renal Trials and Collaborative Studies., Pediatr Transplant, 17, 149, 10.1111/petr.12034
Garland, 2007, Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases., N Engl J Med, 356, 1928, 10.1056/NEJMoa061760
Dillner, 2010, Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial., BMJ, 341, c3493, 10.1136/bmj.c3493
Vaziri, 2012, Effect of uremia on structure and function of immune system., J Ren Nutr, 22, 149, 10.1053/j.jrn.2011.10.020
Chonchol, 2006, Neutrophil dysfunction and infection risk in end-stage renal disease., Semin Dial, 19, 291, 10.1111/j.1525-139X.2006.00175.x
Dalrymple, 2008, Epidemiology of acute infections among patients with chronic kidney disease., Clin J Am Soc Nephrol, 3, 1487, 10.2215/CJN.01290308
Fadrowski, 2004, Varicella zoster virus: Vaccination and implications in children with renal failure., Expert Rev Vaccines, 3, 291, 10.1586/14760584.3.3.291
Esposito, 2014, Vaccine administration in children with chronic kidney disease., Vaccine, 32, 6601, 10.1016/j.vaccine.2014.09.038
Gomez-Lobo, 2014, Immunogenicity of a prophylactic quadrivalent human papillomavirus L1 virus-like particle vaccine in male and female adolescent transplant recipients., Pediatr Transplant, 18, 310, 10.1111/petr.12226
Kumar, 2013, Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients., Am J Transplant, 13, 2411, 10.1111/ajt.12329
Schiller, 2009, Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials., J Infect Dis, 200, 166, 10.1086/599988
Brown, 2014, Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18., Vaccine, 32, 5880, 10.1016/j.vaccine.2014.08.004
Brown, 2011, The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay., Hum Vaccin, 7, 230, 10.4161/hv.7.2.13948